Browse EIF4H

Summary
SymbolEIF4H
Nameeukaryotic translation initiation factor 4H
Aliases WSCR1; KIAA0038; WBSCR1; Williams-Beuren syndrome chromosome region 1; eIF-4H; Williams-Beuren syndrome chro ......
Chromosomal Location7q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, perinuclear region
Domain PF00076 RNA recognition motif. (a.k.a. RRM
Function

Stimulates the RNA helicase activity of EIF4A in the translation initiation complex. Binds weakly mRNA.

> Gene Ontology
 
Biological Process GO:0001731 formation of translation preinitiation complex
GO:0002181 cytoplasmic translation
GO:0006413 translational initiation
GO:0006417 regulation of translation
GO:0006446 regulation of translational initiation
GO:0010608 posttranscriptional regulation of gene expression
GO:0022613 ribonucleoprotein complex biogenesis
GO:0022618 ribonucleoprotein complex assembly
GO:0034248 regulation of cellular amide metabolic process
GO:0071826 ribonucleoprotein complex subunit organization
GO:0097010 eukaryotic translation initiation factor 4F complex assembly
Molecular Function GO:0003725 double-stranded RNA binding
GO:0003727 single-stranded RNA binding
GO:0003743 translation initiation factor activity
GO:0004386 helicase activity
GO:0008135 translation factor activity, RNA binding
GO:0033592 RNA strand annealing activity
GO:0034057 RNA strand-exchange activity
GO:0043021 ribonucleoprotein complex binding
GO:0043024 ribosomal small subunit binding
GO:0045296 cadherin binding
GO:0050839 cell adhesion molecule binding
GO:0097617 annealing activity
GO:0098631 protein binding involved in cell adhesion
GO:0098632 protein binding involved in cell-cell adhesion
GO:0098641 cadherin binding involved in cell-cell adhesion
Cellular Component GO:0005844 polysome
GO:0005913 cell-cell adherens junction
GO:0016281 eukaryotic translation initiation factor 4F complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-157279: 3' -UTR-mediated translational regulation
R-HSA-72662: Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S
R-HSA-72737: Cap-dependent Translation Initiation
R-HSA-72613: Eukaryotic Translation Initiation
R-HSA-72706: GTP hydrolysis and joining of the 60S ribosomal subunit
R-HSA-74160: Gene Expression
R-HSA-156827: L13a-mediated translational silencing of Ceruloplasmin expression
R-HSA-392499: Metabolism of proteins
R-HSA-72702: Ribosomal scanning and start codon recognition
R-HSA-72766: Translation
R-HSA-72649: Translation initiation complex formation
Summary
SymbolEIF4H
Nameeukaryotic translation initiation factor 4H
Aliases WSCR1; KIAA0038; WBSCR1; Williams-Beuren syndrome chromosome region 1; eIF-4H; Williams-Beuren syndrome chro ......
Chromosomal Location7q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between EIF4H and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolEIF4H
Nameeukaryotic translation initiation factor 4H
Aliases WSCR1; KIAA0038; WBSCR1; Williams-Beuren syndrome chromosome region 1; eIF-4H; Williams-Beuren syndrome chro ......
Chromosomal Location7q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of EIF4H in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.56 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolEIF4H
Nameeukaryotic translation initiation factor 4H
Aliases WSCR1; KIAA0038; WBSCR1; Williams-Beuren syndrome chromosome region 1; eIF-4H; Williams-Beuren syndrome chro ......
Chromosomal Location7q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of EIF4H in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0860.608
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0670.985
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1020.968
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1560.539
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0370.987
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.40.889
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0370.94
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0870.97
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1770.945
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3670.873
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8260.813
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0190.81
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of EIF4H in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolEIF4H
Nameeukaryotic translation initiation factor 4H
Aliases WSCR1; KIAA0038; WBSCR1; Williams-Beuren syndrome chromosome region 1; eIF-4H; Williams-Beuren syndrome chro ......
Chromosomal Location7q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EIF4H. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolEIF4H
Nameeukaryotic translation initiation factor 4H
Aliases WSCR1; KIAA0038; WBSCR1; Williams-Beuren syndrome chromosome region 1; eIF-4H; Williams-Beuren syndrome chro ......
Chromosomal Location7q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EIF4H. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EIF4H.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolEIF4H
Nameeukaryotic translation initiation factor 4H
Aliases WSCR1; KIAA0038; WBSCR1; Williams-Beuren syndrome chromosome region 1; eIF-4H; Williams-Beuren syndrome chro ......
Chromosomal Location7q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EIF4H. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolEIF4H
Nameeukaryotic translation initiation factor 4H
Aliases WSCR1; KIAA0038; WBSCR1; Williams-Beuren syndrome chromosome region 1; eIF-4H; Williams-Beuren syndrome chro ......
Chromosomal Location7q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of EIF4H expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolEIF4H
Nameeukaryotic translation initiation factor 4H
Aliases WSCR1; KIAA0038; WBSCR1; Williams-Beuren syndrome chromosome region 1; eIF-4H; Williams-Beuren syndrome chro ......
Chromosomal Location7q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between EIF4H and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolEIF4H
Nameeukaryotic translation initiation factor 4H
Aliases WSCR1; KIAA0038; WBSCR1; Williams-Beuren syndrome chromosome region 1; eIF-4H; Williams-Beuren syndrome chro ......
Chromosomal Location7q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting EIF4H collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.